At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Not Yet Opened 03-30 16:00:00 EDT
0.9984
+0.1847
+22.70%
盘后0.9310
-0.0674-6.75%
19:59 EDT
High1.00Low0.7800Vol204.33K
Open0.8183D1 Closing0.8137Amplitude27.04%
Mkt Cap2.09MTradable Cap1.77MTotal Shares2.09M
T/O185.34KT/O Rate11.51%Tradable Shares1.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
GlobeNewswire  ·  03-30 20:32
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
Reuters  ·  03-27
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
THOMSON REUTERS  ·  03-27
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine reports successful ongoing treatment in CMND-100 trial
TIPRANKS  ·  03-19
Clearmind Medicine reports successful ongoing treatment in CMND-100 trial
Clearmind Medicine reports ongoing Phase I/IIa CMND-100 trial treatment at U.S. sites for alcohol use disorder
Reuters  ·  03-19
Clearmind Medicine reports ongoing Phase I/IIa CMND-100 trial treatment at U.S. sites for alcohol use disorder
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in Its FDA-Approved Cmnd-100 Phase I/Iia Clinical Trial for Alcohol Use Disorder
THOMSON REUTERS  ·  03-19
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in Its FDA-Approved Cmnd-100 Phase I/Iia Clinical Trial for Alcohol Use Disorder
Clearmind Medicine reports publication of six Hong Kong patents for PEA-psychedelic combination therapies
Reuters  ·  03-17
Clearmind Medicine reports publication of six Hong Kong patents for PEA-psychedelic combination therapies
Clearmind Medicine announces Hong Kong patent filing for depression therapy
TIPRANKS  ·  03-13
Clearmind Medicine announces Hong Kong patent filing for depression therapy
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
THOMSON REUTERS  ·  03-13
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment
Reuters  ·  03-12
BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment
SciSparc-Controlled NeuroThera Labs Publishes PCT Patent for MEAI-PEA Weight Loss and MASLD Therapy
Reuters  ·  03-12
SciSparc-Controlled NeuroThera Labs Publishes PCT Patent for MEAI-PEA Weight Loss and MASLD Therapy
BUZZ-Clearmind rises after advancing trial of alcohol-use disorder drug
Reuters  ·  03-11
BUZZ-Clearmind rises after advancing trial of alcohol-use disorder drug
Clearmind advances recruitment for CMND-100 trial’s third cohort
TIPRANKS  ·  03-11
Clearmind advances recruitment for CMND-100 trial’s third cohort
Clearmind Medicine advances third-cohort enrollment for Phase I/IIa CMND-100 alcohol use disorder trial
Reuters  ·  03-11
Clearmind Medicine advances third-cohort enrollment for Phase I/IIa CMND-100 alcohol use disorder trial
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
GlobeNewswire  ·  03-11
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD
Reuters  ·  03-04
BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD
Clearmind Medicine Inc - Dsmb Approves Continuation of Phase I/Iia Cmnd-100 Trial in AUD
THOMSON REUTERS  ·  03-04
Clearmind Medicine Inc - Dsmb Approves Continuation of Phase I/Iia Cmnd-100 Trial in AUD
Clearmind Medicine wins DSMB approval to advance CMND-100 AUD trial to third cohort
Reuters  ·  03-04
Clearmind Medicine wins DSMB approval to advance CMND-100 AUD trial to third cohort
Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs
Reuters  ·  02-20
Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs
Clearmind Medicine files to sell 8.17M common shares for holders
TIPRANKS  ·  02-18
Clearmind Medicine files to sell 8.17M common shares for holders

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--